ALK-N001/QHL-1618 for injection received the drug clinical trial approval notice in April 2025.
November 1, 2025
Source: drugdu
87
SecuritiesDaily News Network - AnglikangOn October 30, the company issued an announcement stating that, in response to inquiries from researchers, it received approval for clinical trials of its injectable ALK-N001/QHL-1618 in April 2025. As of now, it is in the dose escalation phase of Phase I clinical trials, and the research and development process is progressing according to the original plan. Regarding the ALK-N002/IMD-1005 project, Yafei Bio and Affinity are still carrying out internal approval procedures. Once the approval is completed, the company will fulfill its information disclosure obligations in a timely manner.
https://finance.eastmoney.com/a/202510303550388416.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
